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Background: This randomized phase II study was conducted to evaluate the efficacy of doxorubicin and
docetaxel (DOC) administered either as a combination, an alternating or a sequential regimen in women with
metastatic breast cancer. Secondary objectives included overall response, time to progression, survival and
safety.
Patients and methods: Patients with breast cancer (n = 123) were randomized to receive doxorubicin and
DOC either in combination (60 mg/m2 of each drug), or by alternated or sequential schedule (100 mg/m2 DOC
and 75 mg/m2 doxorubicin) every 3 weeks for a maximum of eight cycles as first chemotherapy for stage IV disease.
A second randomization allocated patients from each arm to receive prophylactic oral ciprofloxacin or no therapy
to prevent febrile neutropenia.
Results: Patients received a median of eight cycles. In an intention-to-treat analysis, the overall response was
63%, 52% and 61% in the combination, alternating and sequential schedules, respectively. Corresponding rates
of complete response were 15%, 14% and 11%. Grade 4 neutropenia was common in all arms (81%) and,
together with febrile neutropenia, was significantly more frequent with the combination. Prophylaxis with
ciprofloxacin did not reduce the incidence of febrile neutropenia or infection. Other frequent non-hematological
adverse events included alopecia, nausea, vomiting, stomatitis and asthenia. Congestive heart failure only
occurred in the combination arm (10%).
Conclusion: All three schedules are feasible and endowed of good therapeutic activity. In view of the more
pronounced toxicity and the risk of cardiac events because of the higher exposure to doxorubicin, the combin-
ation should be least favored when treating women with metastatic breast cancer. Prophylaxis with cipro-
floxacin was ineffective and is not recommended.
Key words: docetaxel, doxorubicin, breast cancer
Introduction
Anthracyclines and the taxanes docetaxel (DOC) and paclitaxel
are the classes of cytotoxic drugs affording the best therapeutic
results for women with breast cancer [1, 2]. In particular, DOC
showed superior antitumor activity over doxorubicin [3], and
studies showed that it also had antitumor activity in women with
anthracycline-resistant disease [4]. Lack of complete clinical
cross-resistance justified the conduct of studies combining the two
drugs in the AT (doxorubicin and docetaxel) [5] and in the TAC
regimens (docetaxel, doxorubicin and cyclophosphamide) [6]. A
phase III comparison in metastatic breast cancer showed superior
activity and efficacy of AT over the standard doxorubicin and
cyclophosphamide [7]. For TAC, superior antitumor activity did
not translate into significant improvement in median time to pro-
gression and overall survival over classical FAC regimen (fluoro-
uracil, doxorubicin and cyclophosphamide) for women with
metastatic breast cancer [8]. Instead, in the adjuvant setting the
TAC regimen improved the disease-free survival (82% versus
74%) over FAC [9].
Metastatic breast cancer is almost always an incurable disease.
Among relevant determinants of such unfavorable course, acquired
multidrug resistance plays an undisputed role. Traditionally,
combination therapy has been developed to try and circumvent
acquired resistance by the concomitant application of drugs with
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different mechanisms of action and non-overlapping toxicities.
However, it is still undetermined what is the best approach for the
optimal application of non-cross-resistant drugs. The Goldie and
Coldman hypothesis [10] calls for alternating non-cross-resistant
drugs as early as possible. According to Norton and Simon [11],
tumor regression is proportional to the dose intensity and the
sequential administration of the drugs. We thought that the avail-
ability of non-cross-resistant drugs endowed of high activity, such
as DOC and doxorubicin, could offer an excellent opportunity to
test in patients the respective merits and limits of different sched-
ules of administration. The topic is of present relevance also in
view of the maturing of data from adjuvant and neo-adjuvant
studies in which different schedules of DOC-containing regimens
are applied [9, 12]. We here report a phase II study in which
women with metastatic breast cancer were randomized to receive
DOC and doxorubicin in combination, in an alternating schedule
or in sequence.
Patients and methods
From November 1996 to January 2000, 123 women aged 18–70 years were
enrolled onto this open-label randomized phase II trial. The study was con-
ducted in accordance with the Declaration of Helsinki after approval of the
ethical committees of the nine participating centers. Written informed consent
was obtained from all patients.
The primary objective of the study was the rate of complete response in the
three groups of treatment. The planned sample size of 41 patients per arm was
determined according to Fleming’s two-stage design. It was assumed that no
treatment schedule would be of further interest if the complete response rate
was <5%. The sample size allowed for testing of the null hypothesis (H0; the
true complete response rate is <5%) versus the alternative hypothesis (HA; the
true complete response rate is >20%) with a power of 93%. Secondary object-
ives included overall response, time to progression (TTP), survival and safety.
Another objective of the study was to test whether oral prophylactic anti-
biotic therapy with ciprofloxacin (500 mg b.i.d. from day 7 to 14) could dras-
tically reduce the frequency of febrile neutropenia which was reported to
account for ∼40% of the patients and 13% of cycles when doxorubicin was
given concomitantly with DOC. Allocation to receive or not receive oral cipro-
floxacin was randomly carried out after stratification for chemotherapy regimen.
If the study could be completed with all the patients required for assessing anti-
cancer treatment effectiveness, two groups of 20 patients, corresponding to
about two groups of 100 cycles, could be allocated to oral ciprofloxacin or not
in the concomitant arm. This number of cycles could allow to detect a decrease
of febrile neutropenia from 13% to 2.5%, with a two-sided significance level
of 5% and a statistical power of 80%.
Entry criteria required histologically confirmed measurable metastatic disease
and performance of a biopsy in case of a single metastatic lesion. Other
requirements included: performance status 0 to 2 [World Health Organization
(WHO) scale]; normal organ function [i.e. normal total bilirubin, AST and
ALT <2.5-fold the upper limits of normal (ULN), alkaline phosphatase <5 ULN,
neutrophil count ≥2 × 109/l, platelets ≥100 × 109/l, hemoglobin ≥10 g/dl,
creatinine <1.6 mg/dl]; normal left ventricular ejection fraction (LVEF) as
measured by radionuclide angiography or echocardiography. No prior chemo-
therapy for metastatic disease or concomitant bisphosphonates were allowed.
Patients could have received adjuvant chemotherapy provided that the total
dose of delivered anthracyclines was no more than 240 mg/m2 of doxorubicin
equivalents delivered at least 1 year before study entry. For the purpose of
calculating prior exposure to anthracyclines, 1 mg of doxorubicin was con-
sidered equicardiotoxic to 1.8 mg of epirubicin [13], or to 0.3 mg of mitox-
antrone. Previous radiotherapy, hormonal therapy (either as adjuvant or for
metastatic disease) or surgery were allowed. Patients were excluded in presence
of pre-existing peripheral neuropathy ≥G2, central nervous system involve-
ment, prior malignancies (other than non-melanoma skin cancer or excised
cervical carcinoma in situ), pregnancy or in absence of adequate contra-
ception.
Treatment plan
Patients in the combination arm received doxorubicin (60 mg/m2)
plus DOC (60 mg/m2) with 1-h interval between drugs; patients in
the alternating and in the sequential regimen received doxorubicin
(75 mg/m2) and DOC (100 mg/m2 infused over 1 h) beginning
with DOC for the alternating regimen (four cycles of DOC altern-
ated with four cycles of doxorubicin), and with doxorubicin for
the sequential regimen (four cycles of doxorubicin followed by
four cycles of DOC) for a maximum of eight cycles. Corticosteroid
premedication was given with DOC administration (8 mg of oral
dexamethasone at 13, 3 and 1 h before DOC infusion and at 12, 24,
36 and 42 h after DOC infusion). In case of repeated febrile
neutropenia (see also below), grade 3 diarrhea, grade 3 stomatitis,
grade 3 nausea and vomiting (despite adequate preventive or
curative medication), DOC was reduced to 75 mg/m2 and doxo-
rubicin to 60 mg/m2 in the alternating and sequential regimens;
while doxorubicin was delivered at 50 mg/m2 without modifying
DOC in the combination arm. Only reduction of doxorubicin (to
60 mg/m2 in the alternating and sequential arms and to 50 mg/m2
in the combination arm) was required for grade 4 thrombocytopenia.
In all regimens in presence of grade 2 peripheral neuropathy only
DOC reduction was planned. Both drugs were decreased in
patients with impaired liver function.
In order to avoid cardiac toxicity the maximum cumulative dose
of doxorubicin equivalents was initially set at 550 mg/m2. In
March 1999 the limit was decreased to 480 mg/m2 in the light of
the observed cardiac toxicity.
Patients randomized to antibiotic prophylaxis received cipro-
floxacin, 500 mg orally twice daily from day 7 to day 14 of each
cycle to evaluate the prevention of febrile neutropenia defined as
grade 4 neutropenia with fever ≥38°C in three determinations
during a 24-h period, or a single elevation above 38.5°C. Hospital-
ization was always performed for the first cases of febrile neutro-
penia at the beginning of the study. Following cases were treated
at home whenever possible and admitted to hospital if fever
>38.5°C persisted for more than 3 days. Patients not randomized
to antibiotic prophylaxis could receive antibiotic prophylaxis only
following febrile neutropenia in a previous cycle. Recombinant
granulocyte colony-stimulating factor (G-CSF) was allowed only
in cases of repeated episodes of febrile neutropenia.
Patient and treatment evaluation
Pre-study evaluation included patient’s medical history, physical
examination, chest X-ray or computed CT scan, complete blood
cell count (CBC), liver and kidney tests, abdominal echography or
computed CT scan, bone scan, ECG and measurement of LVEF.
In case of liver disease CT scan was used to assess response.
Response according to WHO criteria was assessed every other
cycle [14] and toxicity according to the National Cancer Institute
common toxicity criteria (NCI CTC) scale [15] at each visit.
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Biochemistry assessments were made before every cycle, while
CBC was performed weekly and repeated every other day until
recovery in case of grade 4 neutropenia or thrombocytopenia.
LVEF was assessed after a cumulative dose of doxorubicin of
300 mg/m2 and repeated before every cycle once a cumulative
dose of 400 mg/m2 was reached.
All efficacy and safety analyses were performed on the intention-
to-treat population, defined as the patient population who started
at least one cycle of doxorubicin or DOC. Time to progression
was calculated starting from the date of randomization to the date
of first progression. Survival was the time from randomization to
death from any cause. The response rates and rates of toxic events
were compared between the three groups with the Fisher’s exact
test (5% significance level). Categorical data were compared by
chi-square test, while continuous variables were summarized with
at least the median and the range.
Results
Patient characteristics
Of the 123 patients enrolled, 121 received study treatment.
Among enrolled patients, 13 (11%) were found not to meet eli-
gibility criteria (including absence of measurable disease according
to WHO criteria in nine and altered laboratory findings in the
other three patients). Six, five and two of these 13 patients were
enrolled into the alternating, combination and sequential arms,
respectively. Patient characteristics were well balanced between
arms (Table 1). Median age was 53 years (range 24–69) and the
median WHO performance was 0 (range 0–1). Fifty-three patients
(44%) had prior adjuvant chemotherapy, including anthracyclines
in 16 (13%). Visceral involvement was present in the majority of
patients, and liver metastases were present in 46, 43 and 40% of
patients in the combination, alternating and sequential schedules,
respectively.
Overall, the median number of delivered cycles was eight, and
the median relative dose intensity was ≥0.9 for each drug in each
arm. Toxicity caused delay of treatment in 16% of cycles in each
arm, and <10% of cycles were delivered at reduced dose of either
drug. Discontinuation of treatment due to adverse events was
reported in 14 patients (11.5%): two treated with alternating,
seven with combination and five with sequential treatment.
Patients in the combination arm received a higher median total
dose of doxorubicin (460 mg/m2) than those in the alternating
(294 mg/m2) and sequential (297 mg/m2) regimens. Corresponding
median cumulative dose of DOC was respectively 468, 392 and
388 mg/m2 in the three arms.
Antitumor activity
According to intent-to-treat analysis, the overall response was 63%
(95% CI 47–77%) with the combination, 52% (95 CI 37–68%)
with the alternating and 61% (95% CI 43–76%) with the sequential
regimen (Table 2). Corresponding rates of complete response
were 15%, 14% and 11%, respectively. No statistically significant
difference among treatments was present. At a median 22 months
of follow-up, median time to progression (TTP) was 36 weeks
(95% CI 28–49 weeks) for the combination, 34 weeks (95%
CI 27–66 weeks) for the alternating schedule and 33 weeks (95%
CI 28–42 weeks) for the sequential schedule. Only a minority of
patients progressed while on therapy (10%, 19% and 13% with
combination, alternating and sequential regimens, respectively).
However, a high proportion of patients (44% in the combination
arm and 29% in each of the other two arms) were censored in the
analysis of TTP because they received a different therapy (either
hormonal or chemotherapy) even in the absence of progression at
end of study treatment. With respect to survival, with 41 patients
per group the three groups were not noticeably different. The esti-
mated overall survival probabilities were 90% at 1 year, 62% at
2 years and 46% at 3 years. The overall median survival time was
34 months (95% CI 25–46 months).
Toxicity
Grade 4 neutropenia was the most frequent toxicity and occurred
in 83%, 88% and 71% of patients in alternating, combination and
sequential arms, respectively. Febrile neutropenia was signifi-
Table 1. Patient characteristics
adj CT, adjuvant chemotherapy; Alt, alternating arm; Comb, combination 
arm; Seq, sequential arm; WHO PS, World Health Organization 
performance status.
Comb Alt Seq
No. of patients randomized 42 42 39
No. of patients treated 41 42 38
No. of patients eligible 36 36 36
Median age, years (range) 54 (30–68) 52 (30–69) 54 (24–67)
Median WHO PS (range) 0 (0–1) 0 (0–1) 0 (0–1)
Prior (neo) adj CT (%) 19 (46%) 17 (40%) 17 (45%)
Prior anthracyclines (%) 6 (15%) 6 (14%) 4 (11%)
Visceral involvement 27 (66%) 31 (74%) 32 (84%)
Liver involvement 19 (46%) 18 (43%) 15 (40%)
≥3 organs involved 13 (32%) 22 (52%) 17 (45%)
Table 2. Therapeutic effects
Alt, alternating arm; CI, confidence interval; Comb, combination arm; CR, 
complete response; ORR, overall response rate; PR, partial response; Seq, 
sequential arm; TTP, time to progression.
Comb
 (41 patients)
Alt 
(42 patients)
Seq 
(38 patients)
CR 15% 14% 11%
PR 49% 38% 50%
ORR (CR + PR) 63% 52% 61%
95% CI 47, 77% 37, 68% 43, 76%
Median TTP, weeks 36 34 33
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cantly higher (P <0.05) in the combination arm (22% versus 7% in
the alternating and 0% in the sequential). An analysis of the
neutropenia associated with single-agent doxorubicin and DOC in
the alternating and sequential arms indicated that severe episodes
occurred evenly spread throughout the entire course of treatment
without indication of cumulative toxicity, and that the two drugs
caused similar effects at the selected doses. Antibiotic prophylaxis
did not prevent episodes of febrile neutropenia (14% episodes in
cyprofloxacin-treated patients versus 6% in the control arm) or
infections. Grade 3/4 infections (2%) were only observed with the
combination arm. No septic deaths were reported (Table 3).
The combination regimen was also associated with higher
incidence of grade 3/4 stomatitis (12% versus 5% in both alternating
and sequential arms). Other grade 3/4 toxicities were diarrhea,
nausea, vomiting and asthenia (Table 4). All of them occurred
with similar frequency in the three arms of therapy.
Cardiac toxicity
Cardiac toxicity was more common in the combination arm with
32% events of grade 1 and 2 versus 5% events of grade 1 in the
alternating arm and 11% events of grade 1 and 2 in the sequential
arm. No grade 3 and 4 cardiac toxicity events were reported
except in the combination arm, in which four episodes (10%) of
congestive heart failure (CHF) were observed (Table 5). All the
patients who developed CHF had received a cumulative dose of
doxorubicin equivalents, including prior adjuvant anthracyclines,
of 480 mg/m2 (487 mg/m2 in one patient). One patient also had
received left breast adjuvant radiotherapy and recovered from
cardiac heart failure after 1 year. A second patient had received
previous chemotherapy with epidoxorubicin (210 mg/m2) as
adjuvant treatment 3 years before enrolment and she died from
progression of disease. A third patient was known to have mild
arterial hypertension. The last patient had no cardiac risk factors.
All patients but one recovered from CHF with adequate cardiac
medication.
Discussion
Taxanes and anthracyclines are increasingly used as the option of
choice for treating women with breast cancer. In particular, DOC
and doxorubicin have outstanding antitumor activity and efficacy,
Table 3. Febrile neutropenia and antibiotic prophylaxis
Alt, alternating arm; Comb, combination arm; Seq, sequential arm.
Comb 
(41 patients)
Alt 
(42 patients)
Seq 
(38 patients)
Total 
(121 patients)
Grade 4 neutropenia 88% 83% 71% 81%
Grade 3/4 infection 2% 0 0 1%
Febrile neutropenia 22% 7% 0 10%
Ciprofloxacin 32% 5% 0% 14%
No ciprofloxacin 11% 10% 0% 6%
Table 4. Non-hematological toxicity
Combination (41 patients) Alternating (42 patients) Sequential (38 patients)
All (%) Grade 3/4 (%) All (%) Grade 3/4 (%) All (%) Grade 3/4 (%)
Alopecia 100 – 93 – 97 –
Nausea 68 7 79 5 87 5
Vomiting 61 2 67 12 58 3
Stomatitis 66 12 64 5 71 5
Asthenia 46 5 45 5 61 8
Neurosensory 32 0 38 2 45 0
Diarrhea 24 0 17 5 11 3
Table 5. Incidence of cardiac toxicity
A, doxorubicin; Alt, alternating arm; CHF, congestive heart failure; Comb, 
combination arm; LVEF, left ventricular ejection fraction; n, number of 
patients who developed CHF; NCI CTC, National Cancer Institute 
common toxicity criteria; Seq, sequential arm.
Comb 
(41 patients)
Alt 
(42 patients)
Seq 
(38 patients)
Median A dose 460 mg/m2 294 mg/m2 297 mg/m2
Clinical CHF (n) 4 0 0
Evaluable for LVEF 35 32 32
NCI CTC grade 1 10% 5% 8%
NCI CTC grade 2 22% 0% 3%
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and lack complete clinical cross-resistance [4]. However, these
drugs are being tested in clinical trials as therapy for metastatic
disease or as adjuvant/preoperative systemic treatment without a
formal assessment of the most convenient schedule [2, 6, 9, 16],
thus justifying in-depth analyses to define the optimal modality
for their administration.
Common clinical wisdom supports the concomitant application
of drugs endowed of different mechanisms of action and non-
overlapping toxicity to decrease the probability of resistance.
However, over the years theories suggested that alternating [10] or
sequentially applying non-cross-resistant drugs/combinations
[11] may afford better therapeutic results. In the past, a landmark
work by Bonadonna et al. [17] indicated superior efficacy when
doxorubicin and combination therapy with cyclophosphamide,
methotrexate and fluorouracil (CMF) were administered sequen-
tially rather than in an alternating fashion as adjuvant therapy for
women with high-risk breast cancer. To our knowledge, this is the
first trial directly addressing the question of the antitumor activity
and tolerability of combined, alternating or sequential schedules
of administration of DOC and doxorubicin. The primary end point
of the study was to rank rates of complete response in patients
never treated with chemotherapy for metastatic disease while
attempting to achieve activity as high as described in other trials of
taxanes and anthracyclines [18] or vinorelbine and doxorubicin
[19] in untreated advanced breast cancer.
Many reports describe the combined use of DOC and doxo-
rubicin [5, 6, 16, 20], while fewer deal with their sequential delivery
[21, 22], and one preliminary report describes the use of either
sequential or alternating modality of administration [23]. For our
trial, we used the highest doses feasible without prophylactic
G-CSF whenever doxorubicin and DOC were used as single
agents [24]. For the combination, we referred to the phase I experi-
ence [5]. Of the two schedules recommended for further develop-
ment in that trial, we adopted the one delivering both drugs at the
same dose of 60 mg/m2 [5].
For each schedule of administration, the overall antitumor
activity (63%, 52% and 61% in the combined, alternating and
sequential arms, respectively) and the rate of complete response
(from 15% with the combination to 11% with the sequential regi-
men) fell within the boundaries of the activity reported in other
trials of DOC and doxorubicin, in which the observed overall
response rate ranged from 40 and 77% [6, 16, 20, 21, 25, 26].
Although the study failed to meet the primary objective that was to
achieve a CR rate of 20% in at least one treatment group, the other
findings of this multicenter study are very positive. Given the high
proportion of patients in our study having predominant visceral
disease (74%) and at least three organs involved (43%), the results
should be viewed as an indication of good therapeutic effect for
each tested regimen. The antitumor activity of each tested regimen
must be considered in view of the fact that the combination
approach involved the administration of almost twice as much
doxorubicin and a slightly higher total dose of DOC than the other
two regimens. Time to progression was of the same order of mag-
nitude for each regimen, and of value similar to that reported for
the TAC [8] and for the AT combination [7] in two randomized
phase III trials. However, we feel that our data should be inter-
preted with caution given that most patients were censored from
analysis because they underwent different therapies after end of
study treatment even in the absence of progression.
Data on tolerability offer several opportunities for discussion.
All regimens were feasible, as expected from other reports [6, 16,
20, 21, 25, 26], and as shown by the possibility of delivering a
median eight cycles per patient, with a median dose intensity
>90% of the planned intensity for each drug with each regimen.
When considering hematological toxicity, neutropenia was most
prominent. Overall, a high rate of severe toxicity was observed in
each arm. However, the combination was associated with more
frequent episodes of febrile neutropenia and a 2% rate of moderate–
severe infection. Of interest in this respect, the study also
addressed in a randomized fashion the question whether the use of
prophylactic ciprofloxacin could prevent or reduce incidence and
severity of febrile neutropenia and infections. Such a measure was
proposed by other investigators concerned by the incidence of
severe neutropenia associated with DOC administration [27]. Pro-
phylactic ciprofloxacin did not contribute to any reduction of the
episodes of febrile neutropenia. In view of the risk of selecting
resistant bacteria and the cost of such intervention, our study does
not support the adoption of this measure.
The higher rate of febrile neutropenia seen with the combination
regime could be simply due to the higher total dose of delivered
doxorubicin. However, it could also be due to a toxic enhance-
ment between doxorubicin and DOC. While this was described as
a possibility due to pharmacokinetic interaction for the combin-
ation of doxorubicin and paclitaxel, that also is associated with a
high rate of severe neutropenia [18]. Data about pharmacokinetic
interaction between doxorubicin and DOC are discordant. Indeed,
Itoh et al. reported a sequence-dependent hematological toxicity
with DOC and doxorubicin even in the absence of any meaningful
pharmacokinetic interference between the two drugs [26]. Another
pharmacokinetic study of similar design did confirm the lack of
effects of DOC on plasma exposure to doxorubicin and metabo-
lites, but failed to show any effect of sequence, and documented
that doxorubicin caused an increased exposure to DOC [28].
Together with the higher total dose of doxorubicin delivered, this
possible interaction might explain the higher hematological toxicity
of the combination regime.
Non-hematological toxicity was similar in the three arms of
treatment and in agreement with the data reported [6, 16, 20, 21,
25, 26], although a slightly higher incidence of moderate/severe
stomatitis occurred with the combination. We only observed one
case of grade 4 hand–foot syndrome among patients enrolled in
the sequential arm. This is different from the report of Miller et al.
[21], who described grade 3 and 4 hand–foot syndrome in 42% of
patients receiving sequential doxorubicin and DOC. In considering
the much lower incidence of toxicity in our study, it should be
noted that substantially higher doses of corticosteroids before and
after chemotherapy were adopted in the present trial when delivering
DOC.
A final consideration about tolerability is related to the observed
cardiac effects. Serial cardiac assessments were performed to pre-
vent or recognize early myocardial toxicity due to the administration
of the two drugs. The results clearly show a significantly higher
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incidence of alterations of the LVEF with the combination than
with the other two regimens. The combination regimen was also
associated with a 10% incidence of CHF. Within the context of the
study, this is not surprising in view of the larger total dose of doxo-
rubicin planned and delivered to patients receiving the combin-
ation regimen. Indeed, it is well established that higher total doses
of doxorubicin are responsible for higher risk of heart failure,
reported at 7% at 550 mg/m2, that tends to occur between 4 and
18 weeks after discontinuation of anthracycline [29]. In addition,
previous irradiation to the left chest wall or other risk factors such
as hypertension could have contributed to the episodes of cardiac
toxicity observed in our trial. However, the rate of CHF we report
here is apparently in excess of that in other studies of DOC com-
bined with doxorubicin. Nabholtz et al. [7] described a 3% incidence
of CHF with AT (doxorubicin with DOC), and more recently only
2.4% of CHF was reported in association with the TAC combination
in women with metastatic breast cancer [8] and 4% when the same
combination was applied for early breast cancer [9]. However, in
all the above studies, the total dose of delivered doxorubicin was
always lower than that administered in the present trial. In the
study of AT versus AC it was 378 mg/m2 [7], while it was about
300 mg/m2 when the TAC regimen was used for women with
metastatic breast cancer [8] or as adjuvant therapy for operable
breast cancer [9]. While this observation again points to the different
and higher total dose of doxorubicin delivered in our study as the
main reason for the incidence of clinical cardiac toxicity, it should
be noted that the other taxane, paclitaxel, may cause increased
cardiac toxicity because of pharmacological interaction, and
that this increased risk shows up at a total doxorubicin dose
>360–380 mg/m2, as we delivered with DOC in the present study.
For this reason, a toxic interaction between doxorubicin and DOC
should also be taken into account as a possible contributing factor
at high total dose of concomitantly delivered anthracycline. Such
a possibility is consistent with a preclinical study reporting that
higher concentrations of myocardial doxorubicin and doxorubicinol
in mice could be found after delivery of doxorubicin and DOC in
combination than after administration of single-agent doxorubicin
[30]. Furthermore, a recent report indicated that in human myo-
cardial tissue both paclitaxel and DOC cause induction of meta-
bolic transformation of doxorubicin to cardiotoxic species, even
though DOC does so within a narrower window of enzymatic
activity than paclitaxel, thus projecting for a lower impact than
paclitaxel on clinical effects [31].
In summary, our study showed that doxorubicin and DOC
afford good therapeutic results independently of the schedule of
administration. However, the therapeutic window of the combin-
ation was worse than that of the alternating and sequential regi-
mens because of significantly more hematological and cardiac
toxicity, most likely due to the higher total dose of delivered doxo-
rubicin. Finally, prophylaxis with ciprofloxacin was not effective
in decreasing the incidence of febrile neutropenia. In view of these
findings, the combination of doxorubicin and DOC would appear
as the least favored for women with metastatic breast cancer. The
conclusion whether the combination should be the least favored
regimen also for women with operable breast cancer will have to
await the results of three major ongoing studies in which doxo-
rubicin and DOC are applied either in sequence or in combination
as adjuvant systemic therapy.
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